Pegloticase is recommended for patients with gout in whom xanthine oxidase inhibitor treatment, uricosurics, and other interventions have failed to achieve the SU target and who have recurrent gout flares or non-resolving subcutaneous tophi [43]. This evidence concerns the gene XDH and gout.